How specialists reassess and treat persistent chronic spontaneous urticaria

This guide helps allergy and immunology clinicians review care when chronic spontaneous urticaria remains active. It sets out a practical sequence for assessing disease activity, checking antihistamine treatment and discussing advanced therapies and follow-up.

Begin with a focused reassessment

Chronic spontaneous urticaria (CSU) means chronic hives without an obvious trigger. Allergy & Asthma Network distinguishes it from chronic inducible urticaria, which has a clear trigger, and says CSU accounts for 80% to 90% of chronic urticaria cases.

At each visit, Dunn recommends returning to disease activity, its impact on the patient and how to control it. He says those answers can inform whether to escalate or de-escalate treatment when those choices are available. A concise reassessment can cover the pattern of hives, the effect on the patient and how well the current treatment controls symptoms. Keeping those points together gives the clinician and patient a common basis for discussing the next step.

For testing, Ben-Shoshan says he orders a CBC, CRP, anti-TPO and total IgE for chronic urticaria. He uses the CBC and CRP in part to avoid missing rare vasculitis that can present with chronic urticaria. His reported panel is a concrete example of a specialist's approach to the workup.

Review whether antihistamine treatment is optimized

Mosnaim identifies standard-dose second-generation H1 antihistamines as first-line treatment for CSU. The dose can be increased to as much as four times the standard dose, yet over half of patients remain symptomatic on this therapy. Persistent symptoms are therefore common even when this treatment pathway has been used.

Berger says H1 antagonists are the mainstay and daily dosing is more effective than as-needed use. He also says patients are generally kept on a treatment step for two to three months before stepping up or down. In the reassessment, clinicians can establish whether the patient takes the medicine daily, how long the current step has been in place and whether symptoms continue. These details help distinguish ongoing disease activity from a treatment plan whose use or duration is unclear.

Identify when hives remain refractory

Allergy & Asthma Network defines refractory chronic urticaria as hives that persist despite antihistamines at up to four times regular dosing. At that point, the network says a healthcare provider may turn to more advanced medications that act on inflammation.

Berger says that when patients do not do well on antihistamine therapy, guideline recommendations move to omalizumab, cyclosporine and alternative agents. He estimates that this situation may apply to about half of patients. Lima reports that about 40% of CSU patients in many studies move to advanced therapies, and that about 30% do not respond to omalizumab. These figures describe estimates from different reports, rather than one shared patient group.

For practice owners, the operational step is to make the treatment history easy to review: the antihistamine used, whether it was taken daily, the dose level reached, the time on that step and the patient's reported control. That record supports a focused discussion of whether symptoms persist at the refractory threshold and which treatment options merit discussion.

Discuss targeted and systemic options in context

A review of targeted therapy for antihistamine-refractory CSU says current evidence appears to support omalizumab as first-line targeted therapy. It describes second-line choices as guided by endotype, comorbidity, prior biologic exposure and safety. The review frames selection as dependent on features of the individual case.

Lima says an urticaria guideline update introduces a biologic and a small molecule, with remibrutinib expected alongside omalizumab as a second-line option after antihistamines fail. The FDA approved remibrutinib, marketed as Rhapsido, for adults with CSU based on two clinical trials involving 912 adults at 237 sites in 18 countries. These details give practices a concrete basis for explaining the treatment options under discussion with adult patients.

Dunn says the systemic therapy conversation starts with whether to pursue one, the patient's preference and coverage. For example, a preference for an injection versus an oral medicine may shape the discussion. He describes insurance coverage as a strong challenge, even when a medicine is clinically suitable. A clinic discussion can therefore address both the patient's preferred route and whether the treatment is covered. Treatment decisions for an individual patient belong in a conversation with their own doctor.

Set a follow-up point and review the response

Berger's reported two-to-three-month period on a treatment step offers a reference point for follow-up before stepping up or down. At that review, Dunn's three questions remain useful: how active the disease is, how much it affects the patient and how well it is controlled. The clinician can compare those answers with the treatment step and duration recorded at the prior visit.

The response discussion can also account for how quickly relief matters to the patient. Mosnaim says people with CSU often seek fast relief from itch, hives or swelling. A head-to-head trial of remibrutinib and dupilumab was designed to compare efficacy at early timepoints of four weeks and earlier, which she calls a patient-important outcome. This makes early response a specific topic to include when discussing what the patient hopes treatment will improve.

This page is general education only. It is not medical advice. Talk with your own doctor about your health.

Immunologists.com is a business directory and education site. It does not give medical advice, rank or rate care, or refer patients. Listings come from public registry data and are not endorsements.